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ABSTRACT
Purpose: Tumor response and treatment toxicity are related to minimum and maximum tissue temper-
atures during hyperthermia, respectively. Using a large set of clinical data, we analyzed the number of
sensors required to adequately monitor skin temperature during superficial hyperthermia treatment of
breast cancer patients.
Methods: Hyperthermia treatments monitored with >60 stationary temperature sensors were selected
from a database of patients with recurrent breast cancer treated with re-irradiation (23 2Gy) and
hyperthermia using single 434MHz applicators (effective field size 351–396 cm2). Reduced temperature
monitoring schemes involved randomly selected subsets of stationary skin sensors, and another subset
simulating continuous thermal mapping of the skin. Temperature differences (DT) between subsets
and complete sets of sensors were evaluated in terms of overall minimum (Tmin) and maximum (Tmax)
temperature, as well as T90 and T10.
Results: Eighty patients were included yielding a total of 400 hyperthermia sessions. Median DT
was<0.01 C for T90, its 95% confidence interval (95%CI) decreased to 0.5 C when>50 sensors were
used. Subsets of<10 sensors result in underestimation of Tmax up to 2.1 C (DT 95%CI), which
decreased to 0.5 C when>50 sensors were used. Thermal profiles (8–21 probes) yielded a median
DT< 0.01 C for T90 and Tmax, with a 95%CI of 0.2 C and 0.4 C, respectively. The detection rate of
Tmax43 C is85% while using>50 stationary sensors or thermal profiles.
Conclusions: Adequate coverage of the skin temperature distribution during superficial hyperthermia
treatment requires the use of>50 stationary sensors per 400 cm2 applicator. Thermal mapping is a
valid alternative.
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Introduction
Hyperthermia (HT), i.e., increasing tumor temperature to
41-45 C for one hour, is a proven radiotherapy (RT) and
chemotherapy sensitizer [1–3]. HT delivery is monitored using
temperature sensors, but the required minimum number of
sensors has not been identified. Unlike chemotherapy or RT,
delivery of a prescribed HT dose is challenging due to limited
number of sensors, patient-specific anatomy, and patient-spe-
cific response to heat treatment. The HT dose that can be
given often depends on the maximum temperature patients
can tolerate, which is unknown prior to treatment and may
vary in subsequent treatments. In addition, temperature uni-
formity is not guaranteed due to heterogeneous power
deposition and heterogeneous perfusion, which is tissue,
time and temperature dependent [4]. For various tumor
types, e.g., sarcoma, melanoma, head and neck cancer, and
recurrent breast cancer, tumor response and local control
were shown to be related to minimum temperature (Tmin)
and the 90th percentile of temperatures (T90) achieved in
the treatment area during HT [5–16]. In addition, there is a
clear relationship between maximum temperature (Tmax) and
HT associated toxicity [12,15,17–21]. Recent consensus advo-
cate that Tmax should not exceed 43–45 C [4]. This statement
is supported by an observational study of 262 female
patients treated for recurrent breast cancer with reirradiation
(reRT) and HT: no HT associated toxicity occurred when Tmax
remained below 43.0 C, while the probability of a second-
degree burn was 5% when Tmax was 43.7 C [17]. These con-
clusions highlight the need to find the delicate balance
between optimizing HT for best tumor response while mini-
mizing toxicity by avoiding excessively low and excessively
high temperatures.
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Adequate thermometry is critical for successful HT treat-
ments. Techniques to measure temperature during HT
include fiber-optic probes, thermistors and thermocouples
[4,22]. A disadvantage associated with these methods is that
temperature is often recorded using a small number of tem-
perature sensors. The European Society for Hyperthermic
Oncology (ESHO) technical committee recommended a min-
imum of five different locations to measure skin temperature
every minute during superficial HT. But measuring at just five
skin locations may result in under sampling when significant
temperature gradients are present, particularly within large
treatment areas. Spatial temperature gradients of 1.6 C/cm
have been reported for head and neck [23]. Thermal map-
ping is an alternative technique that involves moving single-
sensor probes cyclically over a fixed trajectory to cover mul-
tiple measurement locations with a single sensor. Despite the
lower temporal resolution, mapping significantly improves
the spatial resolution [24].
For recurrent breast cancer treated with reRTþHT, the
reported number of temperature sensors varies between 1
and 82, with a median of 8 per study [9,12,15,17,19,
20,25–27]. Major suppliers of superficial HT equipment offer
4-32 sensors (ALBA ON 4000, Medlogix, Italy) or 4-8 sensors
(BSD-500, Pyrexar, Salt Lake City, UT, USA). At the Academic
Medical Center (AMC, Amsterdam, The Netherlands) tumor
temperatures are monitored with more than 80 sensors
(Figure 1) using a 196-channel thermometry system (UMCU,
Utrecht, The Netherlands).
HT aims to maximize tumor response while minimizing
the risk of HT associated toxicity. To help achieve this goal,
we performed a simulation study using subsets of skin tem-
peratures measured during superficial HT treatments of
patients with recurrent breast cancer treated with reRTþHT
at the AMC. Two reduced temperature monitoring schemes
were considered: (1) subsets of randomly selected stationary
temperature sensors; and (2) a thermal mapping subset.
These subsets were compared in terms of adequate therm-
ometry coverage, thus establishing the minimum required
number of sensors during superficial HT. In addition, we
investigated the proportion of HT sessions in which a
maximum skin temperature exceeding 43.0 C goes
undetected while using smaller subsets of sensors.
Methods
Between February 2015 and June 2017, 137 patients were
treated with RT and superficial HT using one or two applica-
tors of the ALBA 4000 Double-ON system (Medlogix, Rome,
Italy). Of these, 80 patients presented recurrent breast cancer
and were reirradiated with 23 2Gy and five weekly HT ses-
sions. The other 57 patients were excluded from this study
for various criteria identified in Figure 2. Median age at start
of treatment was 66 years (range 40–88). Patients had been
treated previously with surgery (n¼ 79), chemotherapy
(n¼ 47), hormonal therapy (n¼ 44) and radiotherapy (n¼ 80)
with 60.2 ± 8.8 Gy (mean± SD; range 40–76). Nine patients
had macroscopic tumor, whereas in the other 71 patients,
the recurrent tumor had been surgically removed
before reRTþHT.
HT objectives were to elevate temperatures in the target
region to a minimum of 41 C for one hour while maintaining
maximum skin temperatures below 43.5 C to minimize
occurrence of second-degree burns [17]. Skin temperatures
were evaluated in terms of overall minimum (Tmin) and max-
imum (Tmax) temperature, as well as T90 and T10, which are
the 90th and 10th percentile of the temperature measure-
ments during steady state, respectively. HT started within
30–60min after RT. The HT device consisted of single con-
formal contact flexible microstrip applicators (CFMA; Istok,
Fryazino, Russia) operating at 434MHz: models 3H (n¼ 36),
4 H (n¼ 1) and 5H (n¼ 43) with effective field sizes (EFS) of
396, 216 and 351 cm2, respectively [28]. The EFS is defined as
the area enclosed within the 50% contour of normalized spe-
cific absorption rate (SAR), where the normalization was per-
formed at 1 cm depth in a flat homogeneous phantom [29].
A flat water bag containing temperature-controlled circulat-
ing deionized water was placed between antenna and skin
to control skin temperature and couple microwave energy to
the human body. The water temperature was adjusted within
38–42 C to maintain a minimum temperature of 41 C on
the target skin surface.
Figure 1. Typical placement of superficial temperature sensors in a previously irradiated area during a superficial hyperthermia treatment of a patient with recur-
rent breast cancer. (A) At the AMC, multiple 7-point thermocouple probes are placed in the target region, three or four probes are placed in areas with low perfu-
sion, such as the surgical scar (red dashed line), and the remaining probes are spread out over the target region. (B) Most other users spread limited single
temperature sensors to maximize coverage of the target area.
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Temperature monitoring was performed with 7-point cop-
per-constantan thermocouple probes (±0.05 C accuracy;
ELLA-CS, Hradec Kralove, Czech Republic) placed both inter-
stitially and superficially on the skin (Figure 1(A)). The probes
were placed perpendicular to the dominant direction of the
electromagnetic field to avoid self-heating of the thermo-
couple probes. Power of the microwave device was on
for 25 s and then off for 1 s to enable electronically undis-
turbed temperature measurements once every 26 s with a
196-channel thermometry system (UMCU, Utrecht, The
Netherlands). Note that superficial temperature measure-
ments are influenced by water bolus temperature, type of
thermometry and the presence of plastic coating and sur-
rounding catheters around the sensor [30,31] and may thus
indicate a temperature lower than the actual temperature a
few millimeters deep in the skin [17,32]. The superficial tem-
peratures were measured with a median of thirteen 7-point
probes (range 8–21) and 89 sensors (range 60–147), where
broken sensors were excluded from the analysis. No intersti-
tial temperature data are reported in this study.
Subset analysis
The multi-step procedure to randomly select subsets of sta-
tionary sensors is illustrated in Figure 3. First, a patient with
one of its corresponding HT sessions was drawn at random.
Next, several random sensors of each thermocouple probe
positioned on the skin were selected. This resulted in six ran-
dom subsets (with one to six sensors per 7-point probe) and
one non-random selection with all seven sensors of the 7-
point probe. In subsets with two or three sensors per probe,
selected sensors were not allowed to be adjacent. The
parameters Tmin, T90, T10 and Tmax of the session were calcu-
lated for each sensor selection. To increase the statistical sig-
nificance, these steps were repeated 5000 times, i.e., each HT
session was sampled approximately 12 times.
Thermal mapping was simulated as cyclically pulling a
sensor in a sawtooth fashion along the 6 cm trajectory of the
7-point probe with a temperature measurement performed
every 26 s and every 1 cm, which resulted in a seven-fold
reduction in temporal resolution. The transformation of the
full set of stationary temperature measurements into a tem-
poral selection of points representing continuous thermal
mapping is a non-randomized selection process, which we
call ‘thermal profiles’ throughout the manuscript to differenti-
ate from traditional thermal mapping. Table 1 shows an
example of the temporal distribution of the first 20 tempera-
ture measurements. This was performed for all five HT ses-
sions of all 80 included patients, using all available superficial
temperature measurements (Figure 3). All simulations were
implemented in Matlab R2016a (MathWorks, Natick, MA, USA)
using the default random seed.
To compare the different subsets to the full set of sensors,
we calculated their temperature difference (DT) for each simu-
lation. This procedure was repeated for the thermal profile
subset. Furthermore, we compared the results for scar and
other superficial tissue, as well as for different HT applicators.
Finally, we investigated the proportion of treatments where a
Between February 2015 and June 
2017, 137 patients were planned to be 
treated with reirradiation (23 × 2 Gy) 
and superficial hyperthermia (HT). 
Reasons for exclusion: 
- 11 patients had no recurrent breast cancer 
- 19 patients were not treated with 23 × 2 Gy 
- 1 patient received concurrent chemotherapy 
106 patients with recurrent breast 
cancer were treated with 23 × 2 Gy 
and HT 
Reasons for exclusion: 
- 6 patients received <5 HT treatments 
- 1 patient was treated with >1 applicator 
- 18 patients had <60 temperature sensors 
81 patients with recurrent breast 
cancer were treated with 23 × 2 Gy 
and weekly HT with one applicator 
and >60 temperature sensors on the 
skin 
Reasons for exclusion: 
- 1 patient was lost to follow-up 
80 patients were included, resulting in 
a total of 400 HT sessions  
Figure 2. Patient inclusion/exclusion flowchart.
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Tmax 43.0 C was identified using the full set of sensors.
Using a random selection of these sensors, we simulated the
proportion of subsets that still identified a Tmax 43.0 C.
Thermometry coverage is well characterized by T90 and
Tmax, which correlate with tumor response and toxicity,
respectively. We define thermometry coverage as adequate if
DT 95% CI 0.5 C for both T90 and Tmax. This criterion is
based on accepting maximum detected temperatures of
43.0 C, with a deviation0.5 C. True maximum tempera-
tures may rise up to 43.5 C, which presents a very small
probability (3%) of a second-degree burn [17]. Finally, we
investigated spatial temperature gradients on the skin.
Statistical analysis
No correction for stratified sampling was applied because we
analyzed the highest and lowest temperature values and not
the median or average. Median treatment parameter statis-
tics, 25th and 75th interquartile and 95% CI are reported.
80 recurrent breast cancer patients treated at the AMC between February 2015 and June 2017 
with reirradiation (23×2 Gy) and five weekly sessions of 434 MHz hyperthermia (HT) 
Thermal mapping simulation Stationary sensors simulation 
Step 1. Thermal mapping was simulated for all 
five HT sessions of the 80 included patients, 
according to the sawtooth profile introduced in 
Table 1. This was performed for all 7-point 
thermocouple probes positioned on scar or 
skin tissue. 
Step 2. One patient was drawn at random.   
Step 3. One session out of five was drawn at
random. 
Step 4. For each 7-point thermocouple probe
positioned on scar or skin tissue during the HT 
session, six times a random selection of the 
sensors was performed with an increasing 
number of sensors per probe and once a non-
random selection:  
a. Random selection of one sensor per probe; 
b. Random selection of two sensors per probe 
(not allowed to be adjacent); 
c. Random selection of three sensors per probe 
(not allowed to be adjacent); 
d. Random selection of four sensors per probe; 
e. Random selection of five sensors per probe; 
f. Random selection of six sensors per probe; 
g. Selection of all seven sensors per probe. 
Step 5. Temperature parameters per HT session were calculated, including minimum and maximum 
temperature, and T90 and T10, which are the 90th and 10th percentile of temperature measurements 
during steady state, respectively.  
Step 6.  
a. Steps 1 and 5 were repeated 400 times to generate the results of the thermal mapping 
simulation. 
b. Steps 2-5 were repeated 5000 times to generate the results of the simulation study consisting 
of stationary sensors.  
Figure 3. Simulation steps for thermal mapping and stationary sensors subsets.
Table 1. The selection of the first 20 temperature measurements to simulate thermal mapping with thermal profiles using clinical data from stationary 7-point
thermocouple probes.
Temperature measurement 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Time (seconds) 26 52 78 104 130 156 182 208 234 260 286 312 338 364 390 416 442 468 494 520
Sensor 1 x x x
Sensor 2 x x x
Sensor 3 x x x
Sensor 4 x x x
Sensor 5 x x x
Sensor 6 x x x
Sensor 7 x x
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Results
The DT between the complete set (range 60–147 sensors)
and randomly selected subsets of superficial sensors (range
8–126 sensors) during a HT session are displayed in Figure 4.
In general, Tmin and Tmax show more variation than T90 and
T10. Remarkably, T90 and T10 have a median temperature
difference<0.01 C across the different subsets of sensors
and small 95% CI, which decrease below 0.5 C when
using>50 and>30 sensors for T90 and T10, respectively.
Small subsets of sensors result in overestimation of Tmin and
underestimation of Tmax (Figure 4), and by increasing the
number of sensors the over and underestimation of Tmin and
Tmax decreased, respectively. The median DT associated with
Tmax was<0.01 C when>20 sensors were randomly
selected, its 95% CI decreased below 0.5 C when>50 sen-
sors were selected. Thermal profiles (17 profiles, median 13
trajectories, range 8–21) showed a median DT<0.01 C for
T90 and Tmax for all 400 HT sessions. The corresponding 95%
CI were small: 0.2 C and 0.4 C for T90 and Tmax, respect-
ively (Figure 4).
A Tmax43.0 C was identified in 50.0% of the HT sessions
(200 out of 400) and in 50.5% of the simulations (2524 out of
5000). Figure 5 shows that at least 50% of the sessions with
temperatures43.0 C were not detected when 20 sensors
were used. Doubling the number of sensors to 40 increased
the detection rate to 80%. Thermal profiles identified
treatments with temperatures43.0 C in 85% of the simula-
tions, which is comparable using 50 stationary sensors.
Finally, when the temperature results of scar were ana-
lyzed separately from other superficial tissue, the tempera-
ture differences of scar presented lower absolute medians
and smaller DT 95% CI for all four parameters (Tmin, T90,
T10 and Tmax). For example, for subsets of<10 stationary
sensors the median DT Tmax was 0.1 C (scar) vs. 0.4 C
(other superficial tissue). Furthermore, for patients treated
with the 3H applicator (EFS¼ 396 cm2, n¼ 36) the tem-
perature difference showed wider DT 95% CI for all four
parameters compared to the 5H applicator (EFS¼ 351 cm2,
n¼ 43). For example, for subsets of<10 stationary sensors,
the DT 95% CI of Tmax was 2.7 C (3H) vs. 1.7 C (5H).
In the 400 HT sessions, the median maximum spatial tem-
perature gradient measured on the skin was 1.1 C/cm
(range 0.3–1.9 C/cm).
Discussion
A simulation study was performed using clinical superficial
temperature measurements of HT treatments of patients with
recurrent breast cancer treated with reRTþHT at the AMC.
Using a large set of clinical data with detailed temperature
recordings (60 sensors), subsets with an increasing number of
skin temperature sensors were randomly selected. The
Figure 4. Tukey boxplots of the temperature difference (DT) between randomly selected subsets (5000 simulations) and the complete set of sensors during a HT
session. The DT Tukey boxplot for the thermal profile analysis that represents thermal mapping (TM) is displayed separately (400 simulations). The median (red hori-
zontal line), 25th and 75th percentiles (lower and upper limits of the rectangular box), as well as the 95% confidence intervals (bracketed vertical lines) of the max-
imum temperature (Tmax), T10, T90 and minimum temperature (Tmin) are displayed for an increasing number of randomly selected temperature sensors in patients
with recurrent breast cancer. The median number of stationary sensors analyzed per bin was 110,983 (range 1386–259,041).
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corresponding Tmin, T90, T10 and Tmax parameters were calcu-
lated. A similar analysis was performed for another subset of
the clinical data, where we simulated the use of ther-
mal mapping.
We found that T90, T10 and Tmax are generally robust
parameters that can be detected within 0.5 C as measured
by the DT 95% CI using:>50 stationary sensors (T90 and
Tmax),>30 stationary sensors (T10), or using thermal profiles
(T90, T10 and Tmax). Furthermore, median DT of T90 and T10
was <0.01 C even when using<10 sensors. These findings
indicate that T90 and T10 parameters can be used to com-
pare HT treatments between different HT centers or between
different sources in literature. However, for comparison pur-
poses, we recommend a DT 95% CI1.0 C, which implies
the use of at least 20 stationary sensors or thermal profiles.
Regardless of the comparison, the quality of thermometry
remains highly dependent on a rigorous spatial sensor distri-
bution that should capture all heterogeneities in superficial
tissue, including scars. Note that T90 and T10 derived from
skin temperature sensors do not represent the dose in the
entire tumor. The quality of hyperthermia treatment is more
dominantly determined by interstitial temperature (dose) val-
ues, the ESHO technical committee therefore strongly advises
to measure both superficial and interstitial temperatures dur-
ing hyperthermia treatment [4].
The minimum and maximum temperatures deviate signifi-
cantly for a low number of sensors (Figure 4). For <10 sen-
sors Tmax can be underestimated with a DT 95% CI of 2.1 C.
This can have serious implications for the estimated toxicity
based on temperature values during HT, since the probability
of a second-degree burn will significantly increase when a
Tmax of 43 C is underestimated by 2.1 C [17]. To reduce the
risk of missing a temperature peak, one would need>100
temperature sensors on the skin during HT treatment
(Figure 5). However, even our complete set of thermometry
does not fully cover the entire treatment area. Sensors within
a probe are located at 1 cm distance, thus a temperature
peak of 44.0 C is unlikely but theoretically possible between
two neighboring sensors both measuring 43.0 C, based on
the highest expected gradients of 1.9 C/cm. Such a tempera-
ture peak would still be below the typical pain threshold
of 44.5 C [21,33] and would give 10% probability on a
second-degree burn [17]. However, the distance between dif-
ferent probes positioned on the skin was more than 1 cm
(Figure 1(A)). It would thus be necessary to place a tempera-
ture sensor on every 1 cm2 if one would want to limit the
maximum possible temperature peak to 44.0 C throughout
the target area. In alternative, the maximum temperature lim-
its during HT treatment could be reduced depending on the
number of sensors that was used (Figure 4), For example,
when<10 sensors were placed on the skin, a reduction of
0.9 C in the maximum temperature limit, from 43.7 C to
42.8 C, would leave 25% of the HT sessions at risk for
undetected temperatures above 43.7 C, i.e., 5% probability
on a second-degree burn [17].
Thermal mapping is a strategy to increase thermometry
coverage using a relatively low number of sensors. There are
many thermal mapping protocols, e.g., mapping a trajectory
of 14 cm in 1 cm increments, performed at 5min intervals
[34] or using essentially stationary sensors with whom a man-
ual map is performed 2–3 times during treatment [24].
Without loss of generality, we choose to implement a simple,
logical and generic thermal mapping procedure with our
dataset. The implemented thermal mapping procedure
entails more thermal profiles per treatment (17 profiles) than
standard practice reported in literature for thermal mapping
(2–10 maps), furthermore shorter trajectories (6 cm) were
taken into account than standard practice reported in litera-
ture (14 cm). In our study, thermal profiles performed much
better than the same number of stationary sensors (median
13, range 8–21); and its performance was comparable to
31–40 stationary sensors in terms of Tmin, T90, T10 and Tmax
Figure 5. Normalized percentage of simulations that identify a maximum temperature (Tmax) 43.0 C (2524 simulations) as a function of randomly selected
sensors. The result of thermal profiles, which represents thermal mapping (TM), is displayed separately (85%; 200 simulations). Tukey boxplots show the median
(red vertical line), 25th and 75th percentiles (lower and upper limits of the rectangular box), as well as 95% confidence intervals (bracketed horizontal lines) of the
number of sensors when n sensors per 7-point probe are selected. The solid circles represent the results per interval of sensors in bins of 10. The median number of
stationary sensors analyzed per bin was 51,589 (range 1656–119,510).
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(Figure 4). It increased the detection rate of temperatures
above 43 C from 40% to 85% (Figure 5). Therefore, thermal
mapping is strongly recommended when there are only a
few sensors available, as with current commercially available
superficial HT equipment, under the condition that thermal
mapping is performed at least every 5–10minutes to gain
sufficient maps during the treatment. The effectiveness of
thermal mapping could be further extended by optimizing
the mapping trajectories, the acquisition time, and steps per
map, so that the density of sampled temperature points
under the applicator is increased.
Part of the temperature sensors were placed on the surgi-
cal scar (28.8%), which is a tissue that tends to overheat due
to poor perfusion. The scar showed smaller DT 95% CI than
other superficial tissue for all four parameters. We believe
this is because sensors on other superficial tissue are distrib-
uted over a much wider treatment area with well vascular-
ized tissue, while the scar is mostly concentrated in the
middle of the treatment area and poorly vascularized, and
thus shows less variation.
Our study was performed mainly with CFMA applicators
with relatively large EFS (351–396 cm2). For applicators with
smaller EFS, it is plausible to assume that less temperature
sensors are required, though temperature gradients may also
be larger within the EFS region of smaller applicators, thus
requiring a higher spatial resolution. When comparing the
5H (351 cm2) and 3H applicator (396 cm2), we found that
patients treated with the 3H applicator had a wider DT 95%
CI. We hypothesize that this is due to wider spacing of
probes over the larger applicator aperture. Thus, the required
minimum number of sensors to adequately monitor tempera-
ture parameters depends on applicator size and type.
Furthermore, there will also be a tumor-specific, e.g., micro-
scopic vs. macroscopic disease, and patient-specific compo-
nent, e.g., presence of scars. It should be investigated
whether the results of this study are valid for a wider range
of applicators, devices and disease types. Nevertheless, this
study indicates that there is a need for much higher spatial
resolution of temperature sensors than is now general stand-
ard practice.
Conclusions
The quality assessment of superficial HT treatment delivery is
dependent on temperature feedback from superficial and
interstitial temperature readings. To this date, the minimum
spatial coverage requirements have not been fully addressed.
Based on our study, we conclude that to adequately monitor
superficial temperature during superficial HT,>50 stationary
sensors per 400 cm2 applicator are required. Although we
advise>100 sensors on the skin to reduce the risk of missing
a temperature peak. As an alternative to>50 sensors, the
use of continuous thermal mapping with approximately 13
sensors would provide similar effective results in terms of
temperature coverage. When only a lower number of sensors
is available, the maximum temperature limit during HT
should be decreased as a function of the number of sensors
used, to minimize toxicity from unrecorded temperature
peaks. Our findings indicate that the T90 and T10 parameters
can be used to compare HT treatments between different HT
centers or different sources in literature with varying number
of sensors, provided a minimum of 20 stationary sensors
is used.
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